Bestselling Dr. Martens sandals that are 'so comfy from day one' are slashed by £42
Dr. Martens has discounted the price of its iconic Gryphon sandals by £42 in time for summer, and shoppers have been praising their sturdiness and comfortability
With a new season officially here, that brings one major thing: spring sales. And Dr. Martens had reduced the price of some of their best-selling styles ahead of summer.
One style in particular that has caught shoppers' attention for being comfy and practical as well as stylish. The Gryphon Tumbled Nubuck Leather Platform Sandals have been discounted from £140 to £98 - that's a huge 30% off.
With the heatwave on its way, now is the perfect time to invest in a new pair of summer sandals, and £42 off is too good a deal to miss out on.
These sandals are the latest update of Dr Martens' iconic Gryphon sandal. So what's different? They've been given lift with a chunky Quad sole, and they're crafted from super-soft Tumbled Nubuck leather that feels just as good as it looks.
Featuring the classic Doc's details you know and love, like the signature yellow welt stitching and branded hardware, these sturdy sandals are built to last. And the beige suede upper is right on trend.
Their durability is one of their selling points and a feature that shoppers love the most. One satisfied shopper said: "For someone hard on shoes - these are perfect! Very comfortable and the thick Doc soles are perfect for all terrain. Wore them on an African adventure and they have withstood water, sand, rocks, shale and everything in between and still look like they came out the box."
Another bonus of these sandals is how comfy they are. This is not always the case with Dr Martens shoes, which often have to be broken in. However, this pair is ready to go from the get-go. A second shopper added: "Look good, feel great. No rubbing, even when out walking for hours. Wish I bought these in the black leather as well. Will do if we get a summer!"
It's worth bearing in mind that these may not work for wider feet, as shoppers have stated they can be quite tight across the width of your foot. One shopper wrote: "Look lovely, feel soft but not suitable for wide feet, sent back."
A few other sandals we're loving for the summer include the UGG Goldenstar Sandals in Chestnut, priced at £110, and the Clarks Evamar Wish Leopard Print Sandals, priced at £95.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
a day ago
- Daily Mail
New Dr Martens boss plans revival by focusing on shoes and sandals as well as boots
The new boss of Dr Martens plans to revive it by focusing on shoes and sandals as well as its boots. Ije Nwokorie, who took over as chief executive at the start of the year, said the 'narrow focus on boots failed to take full advantage' of other areas of the business. He also said that Dr Martens must wean itself off an over-reliance on discounts. 'We're shifting our strategy to broaden our focus and give people more reasons to buy Dr Martens,' said Nwokorie. 'The strategy the business had broke growth in boots, built awareness around the world – but the market shifted away from boots.' Dr Martens reported a slump in annual profits to £34.1million in the year to the end of March, from £97.2million a year earlier. But this was better than expected by City analysts and shares rocketed 25.8 per cent, or 15,45p, to 75.4p. The company expects profits to rise 'significantly' this year.
BBC News
2 days ago
- BBC News
Wollaston-based Dr Martens profits slump by more than 90%
The maker of an iconic brand of footwear have seen its profits fall by more than 90% in the last Martens, based in Wollaston, Northamptonshire, posted pre-tax profits for the year to March of £ figure for the previous year was £93mThe company said UK revenues had been hit by "a challenging market". The Dr Martens design originated in Germany in the 1940s and production started in the UK in 1959, when the Northamptonshire-based Griggs Group bought the patent familiar yellow-stitched boots, made at the factory in Cobbs Lane, Wollaston, have been bought by famous names from the Sex Pistols to the Dalai company has been in the doldrums in recent years, with declining revenues exacerbated by the cost-of-living crisis. Underlying profits in the year to March, which do not include anything exceptional or non-recurring, have dropped from £97.2m to £ group said sales to consumers in the US started to grow in the second half of the year and had continued to increase, but UK revenues had remained lower since the year-end "due to a challenging market". Despite this, Dr Martens said it expected underlying profits to rise "significantly" over the financial year ahead, with analysts expecting a jump to between £54m and £ flagged uncertainty over the impact of higher tariffs, including those imposed by the USA, but said it was holding off from price hikes for the the remainder of group added: "We do recognise that there is continued macroeconomic uncertainty and the full outcome of tariffs is still unknown, and we will monitor this closely through the year and take action as appropriate." Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
Times
2 days ago
- Times
Dr Martens to widen range and cut discounts in quest for profits
The boss of Dr Martens has pledged to ween the struggling bootmaker off discounting, push into new markets and promote other product lines and as it looks to return to profit growth this year. The FTSE 250 retailer said its previous narrow focus on its boots, which accounts for roughly half of the group's total sales, 'failed to take full advantage' of its shoes, sandals and leather goods offering, adding that its direct-to-consumer approach 'led to a loss of coverage and responsiveness in our wholesale offering'. Ije Nwokorie, who succeeded Kenny Wilson as chief executive at the start of the year, told shareholders he plans to shift the business from a 'channel-first to a consumer-first mindset'. 'The strategy that the business had … broke growth in boots, built awareness around the world, but the market shifted away from boots,' he said. Online sales of shoes, mules and sandals grew last year, while sales of its boots, known for their yellow stitching, declined at its shops. He added that his strategy was not 'rocket science', but was about 'broadening our focus to give people more reason to buy our products'. 'We need to become a business that is no longer reliant on any single market, product or channel,' he said. Nwokorie did not expand on what markets he planned for Dr Martens to move into, but said expansion would take place in the year ahead. The company also planned to reduce discounting across its ecommerce and wholesale channels as it aimed to drive full price sales. Nwokorie's turnaround plans were unveiled alongside the group's full-year results. Dr Martens said sales to consumers in the US returned to growth in the second half of the year and continued to increase, but cautioned that UK revenues remained lower since the year end 'due to a challenging market'. Revenues in the year to the end of March fell 10 per cent to £787.6 million, down from £877 million a year earlier. Adjusted pre-tax profit dropped 64 per cent to £34.1 million, which was above the City's forecasts of £30.6 million. Inventory reduction helped lower net debt, excluding lease liabilities, to £94.1 million, down from £177.5 million a year ago. For the present financial year, management expects to deliver profits in line with market expectations of £54 million to £74 million. The Northamptonshire bootmaker has been facing persistent challenges in America, its largest market, including a slowdown in sales as consumers reduced spending and supply chain problems at its distribution centre in Los Angeles. That episode forced the brand to lease temporary third-party warehousing. Shares in the heritage brand, which have fallen more than 80 per cent since listing in 2021 after the company issued multiple profit warnings, were up 15p, or 25 per cent 11¼p, to 75p in afternoon trading as the market reacted to its turnaround pledge. Analysts at Investec believed the strategy 'should unlock a material profit growth story' and its financial targets were realistic. Despite uncertainty around President Trump's tariff regime, Nwokorie said there were no plans to shift production from the US at this point. Dr Martens has shifted its supply chain away from China and expects to produce 62 per cent of its autumn/winter collection in Vietnam, where imports into the US face tariffs of up to 46 per cent. Before the possible tariff introduction, the company said most of its autumn/winter collection would be in transit or in the US by the start of July. Nwokorie said: 'We've looked at different scenarios, but we're dealing with the reality in front of us and we feel confident about our ability to ride these waves,' adding that the company would keep average selling prices for its spring/summer and autumn/winter collections unchanged in the US market. Ije Nwokorie: a 'visionary brand storyteller' While not one of the biggest names in the retail community, Ije Nwokorie has demonstrated to industry observers and City analysts that he knows the power behind the British heritage brand. News of his appointment as chief executive of Dr Martens, announced last April, did not come as too much of a surprise to the market, with some in the City speculating that Nwokorie's appointment as chief brand officer in November 2023 was part of a wider succession plan. As part of the newly created chief brand officer post, Nwokorie was responsible for setting the 'overall brand strategy, vision and direction for the next phase of Dr Martens' growth' — not a bad idea for the retailer that has failed to replicate the influence and sales of its sturdy boots in America that it has in Britain. The former Dr Martens boss Kenny Wilson, who Nwokorie replaced, has described his successor as a 'visionary brand storyteller' whose passion for the bootmaker makes him 'the ideal person to lead the next era'. Nwokorie, who took up his post in February last year, was a senior director at Apple Retail, where he worked from January 2018. He has been on the Dr Martens board since January 2021, when it listed its shares on the London Stock Exchange, amid booming demand for its shoes. Before that, Nwokorie had spent 11 years at Wolff Olins, the global brand consultancy, where he rose to become chief executive. As part of Nwokorie's hopes to drive a brand refresh, he has been quick to up the ante in his leadership team. Last week he announced that Carla Murphy would join the group as chief brand officer from Adidas, where she served as the footwear giant's global senior vice-president. Murphy, who starts in July, will be responsible for looking after Dr Martens' brand, its 'most important asset', Nwokorie said.
